Welcome to LookChem.com Sign In|Join Free
  • or
2-(2-[(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)METHYL]BENZYL)-1H-ISOINDOLE-1,3(2H)-DIONE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

52401-96-4

Post Buying Request

52401-96-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

52401-96-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 52401-96-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,4,0 and 1 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 52401-96:
(7*5)+(6*2)+(5*4)+(4*0)+(3*1)+(2*9)+(1*6)=94
94 % 10 = 4
So 52401-96-4 is a valid CAS Registry Number.

52401-96-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name diphthalimidoyl-o-xylene

1.2 Other means of identification

Product number -
Other names N,N'-o-Xylylen-bis-phthalimid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:52401-96-4 SDS

52401-96-4Relevant academic research and scientific papers

FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS

-

Page/Page column 267; 412, (2008/12/05)

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists

Keenan, Richard M.,Callahan, James F.,Samanen, James M.,Bondinell, William E.,Calvo, Raul R.,Chen, Lichong,DeBrosse, Charles,Eggleston, Drake S.,Haltiwanger, R. Curtis,Hwang, Shing Mei,Jakas, Dalia R.,Ku, Thomas W.,Miller, William H.,Newlander, Kenneth A.,Nichols, Andrew,Parker, Michael F.,Southhall, Linda S.,Uzinskas, Irene,Vasko-Moser, Janice A.,Venslavsky, Joseph W.,Wong, Angela S.,Huffman, William F.

, p. 545 - 559 (2007/10/03)

Previously, we reported the direct design of highly potent nonpeptide 3- oxo-1,4-benzodiazepine fibrinogen receptor antagonists from a constrained, RGD-containing cyclic semipeptide. The critical features incorporated into the design of these nonpeptides were the exocyclic amide at the 8-position which overlaid the Arg carbonyl, the phenyl ring which maintained an extended Gly conformation, and the diazepine ring which mimicked the γ-turn at Asp. In this paper, we investigate conformational preferences of the 8-substituted benzodiazepine analogues by examining structural modifications to both the exocyclic amide and the seven-membered diazepine ring and by studying the conformation of the benzodiazepine ring using molecular modeling, X-ray crystallography, and NMR. We found that the directionality of the amide at the 8-position had little effect on activity and the (E)-olefin analogue retained significant potency, indicating that the trans orientation of the amide, and not the carbonyl or NH groups, made the largest contribution to the observed activity. For the diazepine ring, with the exception of the closely analogous 3-oxo-2-benzazepine ring system described previously, all of the modifications led to a significant reduction in activity compared to the potent 3-oxo-1,4-benzodiazepine parent ring system, implicating this particular type of ring system as a desirable structural feature for high potency. Energy minimizations of a number of the modified analogues revealed that none could adopt the same low-energy conformation as the one shared by the active (S)-isomer of the 3-oxo-1,4-benzodiazepines and 3-oxo-2- benzazepines. The overall data suggest that the features contributing to the observed high potency in this series are the orientation of the 3-4 amide and the conformational constraint imposed by the seven-membered ring, both of which position the key acidic and basic groups in the proper spatial relationship.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 52401-96-4